Focan C, Baudoux A, Beauduin M, Bunescu U, Dehasque N, Dewasch L, Lobelle J P, Longeval E, Majois F, Salamon E
Anticancer Res. 1986 Sep-Oct;6(5):1095-9.
In a prospective randomized trial comparing CMF to CMF + HD-MPA for primary node positive breast cancer patients, the authors evidenced clear improvement of hematological tolerance (especially of WBC - granulocytes counts) to chemotherapy in the group receiving also hormonotherapy. The design of the trial allowed to give the patients overall high doses of CMF therapy in both arms; in the group receiving HD-MPA significantly higher doses of CMF could be administered (96.3-97.8% for CMF + HD-MPA treated patients vs 89.7-91.1% for CMF alone treated patients). The menopausal status did not influence the results.
在一项针对原发性淋巴结阳性乳腺癌患者比较CMF方案与CMF + HD - MPA方案的前瞻性随机试验中，作者发现接受激素治疗的组对化疗的血液学耐受性（尤其是白细胞 - 粒细胞计数）有明显改善。该试验设计允许在两组中给予患者总体高剂量的CMF治疗；在接受HD - MPA的组中，可以给予显著更高剂量的CMF（CMF + HD - MPA治疗的患者为96.3 - 97.8%，而单独接受CMF治疗的患者为89.7 - 91.1%）。绝经状态不影响结果。
